Law360, New York (November 03, 2008, 12:00 AM ET) -- Faced with continued efforts to bring a generic version of Fentora to market, Cephalon Inc. last week filed a second suit against Barr Pharmaceuticals Inc., three months after suing Barr to block generic dosages of Cephalon’s cancer painkiller.
The complaint, lodged Wednesday in the U.S. District Court for the District of Delaware, claims an Abbreviated New Drug Application Barr submitted to regulators constitutes infringement of two patents covering Fentora.
Barr’s decision to file the ANDA constitutes an infringement of U.S. Patent Numbers 6,200,604 and 6,974,590, titled...
Cephalon Sues Barr Again Over Generic Fentora ANDA
To view the full article, take a free trial now.
